Pannysylvania Magazine

Hangzhou, Zhejiang, China – August 26, 2026 – In the booming global metabolic drug market, GLP‑1 peptide drugs have become core therapeutic products for type 2 diabetes and Weight Management. Among all GLP‑1 analogues, Semaglutide CAS NO: 910463‑68‑2 stands out as a blockbuster active pharmaceutical ingredient, featuring long half‑life, stable blood glucose control and obvious weight‑loss effects. As a professional full‑industry‑chain peptide biotech enterprise founded in 2019, Hangzhou Thinheal Pharma‑Tech Co., Ltd. provides high‑purity semaglutide raw materials and one‑stop peptide industrialization solutions for pharmaceutical enterprises across the globe.

Basic Profile of Semaglutide CAS NO: 910463‑68‑2

Semaglutide CAS NO: 910463‑68‑2 is a synthetic modified GLP‑1 receptor agonisT Peptide with molecular formula C₁₈₇H₂₉₁N₄₅O₅₉and molecular weight 4113.58. It appears as white to off‑white powder manufactured via solid‑phase Peptide Synthesis, and needs to be stored at ‑20℃ under cold chain conditions to retain complete biological activity.

Different from native GLP‑1 which only maintains activity for several minutes inside human bodies, semaglutide is modified with fatty acid side chains at lysine sites. The structural modification enables it to bind with human albumin, extending its in‑vivo half‑life to 7 days and supporting once‑weekly administration. Clinically, it achieves hypoglycemic effects by stimulating glucose‑dependent insulin secretion, inhibiting glucagon release, delaying gastric emptying and suppressing appetite. Its applicable scenarios cover type 2 diabetes treatment, overweight and obesity intervention as well as cardiovascular risk reduction.

Global market demand for semaglutide API keeps rising year after year. Industry analysis indicates that global consumption of semaglutide raw materials will reach tens of tons by 2030, bringing huge supply pressure for qualified production enterprises with standard production lines and export qualifications. The complete manufacturing system built by Hangzhou fills this practical market gap.

Hangzhou Thinheal: Trusted Manufacturer of GLP‑1 peptide API

Hangzhou Thinheal Pharma‑Tech runs independent research laboratories and standardized GMP production bases in Hangzhou Qiantang Medicine Valley and Shaoxing coastal industrial zone. Its core team consists of industry practitioners with nearly 20‑year experience in peptide research and mass production, who have mastered complete synthesis, purification and quality control procedures for complex long‑chain peptides including semaglutide.

The enterprise has achieved multi‑ton annual production capacity for chemically synthesized peptides, sitting among leading domestic peptide producers. For semaglutide raw materials, the company has obtained EU‑recognized API export certificates and finished US FDA DMF filing work, strictly following ICH, EP and USP quality specifications. Every production batch goes through rigorous HPLC purity detection, impurity profiling and bioactivity verification, keeping product purity steadily above 98.5%.

Besides bulk supply of commercial‑grade GLP‑1 peptide API, the firm delivers comprehensive peptide CDMO service, covering research outsourcing, pilot‑scale trial production and commercial mass manufacturing. Whether clients require gram‑level laboratory samples, kilogram‑scale clinical trial batches or ton‑level commercial goods, technical staff will optimize synthetic routes to cut manufacturing costs and shorten project lead‑time, helping biotech companies accelerate new drug registration and market launch progress.

Diversified Business Layout

Apart from therapeutic peptide products, the company has constructed a multi‑dimensional product portfolio for different downstream industries.

custom peptide synthesis supports custom development of linear peptides, cyclic peptides, modified long‑chain peptides, impurity reference substances and isotope‑labeled peptides. The service targets university research labs, biotech start‑ups and diagnostic reagent manufacturers, covering output scales from milligram to ton level to satisfy demands from each drug research phase.

As for cosmetic peptide raw material, the enterprise develops multiple anti‑aging, brightening and anti‑wrinkle peptide ingredients. Representative products include acetyl hexapeptide‑8, palmitoyl tripeptide‑5 and snake venom‑simulated peptides, delivering stable and low‑irritation raw materials for cosmetic manufacturers worldwide.

The product catalogue also includes other mainstream therapeutic peptide APIs such as tirzepatide, liraglutide and linaclotide. All these goods are produced under unified cGMP quality management framework.

Core Competitive Strengths as a GMP peptide manufacturer

First, self‑developed synthesis technology for long‑chain peptides. Combined solid‑liquid phase synthesis techniques reduce side reactions and improve overall yield, solving common purification obstacles faced by complex GLP‑1 peptide production.

Second, full‑set global compliance qualifications. ISO9001 certification, national pharmaceutical production permit, high‑tech enterprise credential, EU API export documents and US DMF records help clients complete overseas product registration smoothly.

Third, end‑to‑end technical support. Services span early‑stage peptide sequence design, process optimization, stability assessment, mass production, packaging and cold‑chain logistics. Clients can obtain full‑range support without cooperating with multiple third‑party vendors.

Fourth, global customer service capability. The enterprise takes part in international pharmaceutical exhibitions regularly, and maintains stable long‑term partnerships with purchasers from Europe, North America, Southeast Asia and Latin America.

Get Samples and Quotation

If you are sourcing high‑quality Semaglutide CAS NO: 910463‑68‑2, GLP‑1 related raw materials or seeking reliable peptide processing solutions, feel free to contact Hangzhou Thinheal Pharma‑Tech. You can apply for free sample evaluation and obtain customized quotation according to your actual order volume.

The company sticks to the principle of professionalism and integrity, and keeps supplying cost‑effective standardized peptide raw materials and technical services for global partners, pushing forward the innovative development of global peptide pharmaceutical industry.

About Us

Hangzhou Thinheal Pharma-Tech Co., Ltd. was established in 2019. It is a biopharmaceutical company that combines independent R&D, production, sales and customized research and development and production of peptide products. The core management team is composed of professionals with a pharmaceutical background and nearly 20 years of management experience in the peptide industry.

Media Contact
Company Name: Hangzhou ThinHeal Pharma-Tech Co., Ltd
Contact Person: Media Relations
Email: Send Email
Country: China
Website: https://www.thinhealpeptide.com/